Address
5885 Hollis Street
Emeryville, CA 94608
United States of America (the)
Phone
510 806 1445
Website
Sector
Healthcare
Industry
Biotechnology
Employees
61
First IPO Date
September 26, 2024
| Name | Title | Pay | Year Born |
| Kristen Fortney | Co-Founder, Chief Executive Officer, President, Treasurer, Secretary & Director | 945,200 | 1984 |
| Eric Morgen | Co-Founder, Chief Operating Officer & Director | 714,640 | 1983 |
| Paul D. Rubin | Chief Medical Officer & Executive Vice President of Research | 743,480 | 1954 |
| Dov A. Goldstein | Chief Financial Officer | 0 | 1967 |
| Peng Leong | Chief Business Officer & Therapeutic Area Head of Brain Aging | 0 | N/A |
| Sullivan | Chief Strategy Officer | 0 | N/A |
| Ann C. Neale | Chief Development Officer | 0 | N/A |
| Shane Barton | Senior Vice President of Finance & Accounting | 0 | 1971 |
| Rusty Montgomery | Senior Vice President of Research | 0 | N/A |
| Julie Gammelgard | Senior Vice President of People | 0 | N/A |
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.